Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults

Running, not enrolling

Conditions studied: Acute Kidney Injury

In brief

The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.

Key facts

Study ID

NCT06652100

Run by

BioPorto Diagnostics

People needed

800

Starts

2024-10-28

Expected to finish

2026-01-31

Last updated by the study team

2025-11-19

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and females ≥ 22 years of age. Subjects must be admitted to an Intensive Care Unit and must have a urine sample collected within 24 hours of ICU admission.
• Subjects must have at least one of the following leading to admission to the ICU, or occurring within 24 hours of admission to the ICU:
• Vasoactive medication administration
• Mechanical ventilation
• Hypoxemia requiring oxygen support therapy including Bilevel positive airway pressure (BIPAP) and high flow nasal canula
• Mean arterial pressure (MAP) less than 60 (within 12 hrs. of ICU admission only)
• Serum Lactate greater than 2.5 mmol/L
• History of solid organ transplantation, renal transplantation included only if more than 3 months prior
• History of bone marrow transplantation Subject with signed informed consent.

You may not qualify if…

• Special populations including pregnant and lactating women, prisoners, or institutionalized individuals.
• Subjects receiving Kidney Replacement Therapy in the first 24 hours of ICU admission.
• Subjects diagnosed with active Urinary Tract Infection per institute standard of care at the time of NGAL sampling.
• Subjects with a known history of chronic kidney disease stages 4 and 5 as evidenced by a pre-enrollment estimated GFR of less than 30 mL/min/1.73M2 and under the care of a nephrologist.
• Subjects with any known urothelial, urological or kidney malignancies. Subjects that have had any urologic procedure or urologic surgery immediately prior to admission to the ICU.
• Subjects that have had surgical nephrectomy less than 3 months prior to admission.
• Subjects that have been previously enrolled in this study. Subjects that do not have a baseline sCR within 6 months prior to ICU admission available.
• Subjects that did not sign the informed consent. Subjects enrolled in an interventional pharmaceutical or device clinical trial at time of ICU admission

Where it is running

• The University of Alabama — Birmingham, Alabama, United States
• UC Davis — Sacramento, California, United States
• Yale University — New Haven, Connecticut, United States
• University of Chicago — Chicago, Illinois, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• University of New Mexico — Albuquerque, New Mexico, United States
• Columbia University — New York, New York, United States
• Wake Forest University — Winston-Salem, North Carolina, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.